Your Search for amphotericin b matched 1000 Documents (Page 1 of 34).
You may want to refine your search. Results Indexed by relevance.
Abstract: Complete info about amphotericin B (Fungizone) & treatment for fungal infections & AIDS. ...
http://www.aegis.org/factshts/network/simple/amph.html
File Name: amph.html, Size: 5KB, Last Modified: Sunday, August 20, 2006 at 10:20:52 PM
Abstract: OBJECTIVE: Amphotericin B deoxycholate initial therapy and fluconazole maintenance therapy is the treatment of choice for AIDS-associated cryptococcal meningitis. However, the administration of amphotericin B is associated with considerable toxicity. A potential strategy for reducing the toxicity and increasing the th ...
http://www.aegis.org/aidsline/1998/jan/m9811073.html
File Name: m9811073.html, Size: 10KB, Last Modified: Thursday, January 29, 1998 at 6:29:23 AM
Abstract: The activities of amphotericin B, miconazole, fluconazole, and itraconazole against Trichosporon beigelii were assessed in a mo ...
http://www.aegis.org/pubs/medline/1998/jan/m9812949.html
File Name: m9812949.html, Size: 6KB, Last Modified: Saturday, January 31, 1998 at 10:00:00 PM
Abstract: Further prospective comparative studies are required to compare the various preparations of amphotericin B, but the lipid emulsion described above merits consideration in AIDS patients intolerant of conventional IV amphotericin B therapy. ...
http://www.aegis.org/conferences/hiv-glasgow/1994/p17.html
File Name: p17.html, Size: 6KB, Last Modified: Friday, November 18, 1994 at 8:12:04 PM
Abstract: OBJECTIVE: The present study was undertaken to compare the in vitro efficacy of Liposome encapsulated amphotericin B with deoxycholate amphotericin B in Cryptococcus neoformans strains isolated from immunocompromised patients. METHODS: Clinical specimens were sent to our laboratory ...
http://www.aegis.org/aidsline/1993/nov/m93b4352.html
File Name: m93b4352.html, Size: 9KB, Last Modified: Sunday, November 28, 1993 at 8:12:04 PM
Abstract: <p><b>OBJECTIVE</b>: The present study was undertaken to compare the in vitro efficacy of Liposome encapsulated amphotericin B with deoxycholate amphotericin B in Cryptococcus neoformans strains isolated from immunocompromised patients. <p><b>METHODS</b>: Clinical specimens were sent to our laboratory for culture o ...
http://www.aegis.org/conferences/iac/1993/pob091386.html
File Name: pob091386.html, Size: 5KB, Last Modified: Sunday, June 06, 1993 at 8:12:04 PM
Abstract: Amphotericin B remains the drug of choice for the treatment of life threatening, systemic fungal infections. Nevertheless the use of amphotericin B in the traditional deoxycholate formulation (d-AmB) is limited by severe toxic side effects. Several relatively new formulations have recently received regulatory approval ...
http://www.aegis.org/aidsline/2000/may/a0050111.html
File Name: a0050111.html, Size: 10KB, Last Modified: Sunday, May 28, 2000 at 8:12:04 PM
Abstract: OBJECTIVE: To describe a patient with cryptococcal meningitis treated with the combination of amphotericin B and fluconazole. CASE SUMMARY: A 41-year-old woman with cryptococcal meningitis who was not infected with HIV was treated with a combination of amphotericin B and fluconazole because she did not respond to amph ...
http://www.aegis.org/aidsline/1997/may/m9750873.html
File Name: m9750873.html, Size: 9KB, Last Modified: Wednesday, May 28, 1997 at 8:12:04 PM
Abstract: Opportunistic Infections & Other Complications: Cryptococcal Meningitis. Seattle Treatment Education Project (STEP) Perspective, Vol. 5, No. 2 - July 1993 * 127 Broadway E. Ste 200 Seattle, WA 98102 Laury McKean, RNAmphotericin B, with or without the addition of flucytosine (5-FC) is the typical first-line therapy ...
http://www.aegis.org/pubs/step/1993/step5211.html
File Name: step5211.html, Size: 6KB, Last Modified: Saturday, July 31, 1993 at 11:00:00 PM
Abstract: Amphotericin B susceptibility was measured by a flow cytometric membrane potential assay in Leishmania infantum promastigotes isolated from 11 immunocompetent children treated with liposomal amphotericin B and 19 HIV-infected young adults treated with intralipid amphotericin B. Susceptibility levels were measured by t ...
http://www.aegis.org/aidsline/2000/jan/a0010718.html
File Name: a0010718.html, Size: 10KB, Last Modified: Friday, January 28, 2000 at 8:12:04 PM
Abstract: Cryptococcus neoformans infections in patients with AIDS are often incurable, despite aggressive antifungal therapy. Combination regimens with additive or synergistic drugs could provide additional options for treating cryptococcal meningitis. We evaluated the efficacy of combination therapies using L-743,872, a pneum ...
http://www.aegis.org/aidsline/1997/jul/m9771681.html
File Name: m9771681.html, Size: 10KB, Last Modified: Monday, July 28, 1997 at 8:12:04 PM
Abstract: We conducted a randomized, open-labeled clinical trial to compare the tolerability and efficacy of amphotericin B deoxycholate, prepared in 5% dextrose or Intralipid (Kabi Pharmacia, Saint-Quentin-en-Yvelines, France ), in the treatment of AIDS-associated cryptococcal meningitis in ...
http://www.aegis.org/aidsline/1997/mar/m9730715.html
File Name: m9730715.html, Size: 11KB, Last Modified: Friday, March 28, 1997 at 8:12:04 PM
Abstract: OBJECTIVES--To compare the tolerance, efficacy, and pharmacokinetics of amphotericin deoxycholate (Fungizone) prepared in a parenteral fat emulsion (Intralipid 20%) or glucose in HIV patients with candidiasis. DESIGN--Non-blind randomised controlled trial. SETTING--University hospital; tertiary clinical care. PATIENTS ...
http://www.aegis.org/aidsline/1993/mar/m9330713.html
File Name: m9330713.html, Size: 11KB, Last Modified: Sunday, March 28, 1993 at 8:12:04 PM
Abstract: Complete info about Cryptococcal meningitis & treatment for HIV & AIDS. ...
http://www.aegis.org/factshts/network/simple/menin.html
File Name: menin.html, Size: 6KB, Last Modified: Monday, August 28, 2006 at 8:13:25 AM
Abstract: OBJECTIVE: To explore the early clinical and mycological outcome of combination between amphotericin B and azoles in treatment of cryptococcal meningitis in AIDS. METHOD: This is a randomized, comparative controlled trial, which assigned patients with first episode of AIDS-associated cryptococcal meningitis to treatmen ...
http://www.aegis.org/conferences/iac/2004/mopeb3232.html
File Name: mopeb3232.html, Size: 6KB, Last Modified: Monday, July 12, 2004 at 6:29:23 AM
Abstract: <p><b>OBJECTIVE</b>: Relapses of visceral leishmaniasis are usually seen in HIV infected patients. Antimonial compounds are the drugs of choice to initial therapy for it. Pentamidine, amphotericin B, allopurinol and interferon-gamma are other effective treatments. The new liposomal amphotericin B formulation, a less ...
http://www.aegis.org/conferences/iac/1992/pob3203.html
File Name: pob3203.html, Size: 6KB, Last Modified: Sunday, July 19, 1992 at 8:12:04 PM
Abstract: Amphotericin-B reactivates latent HIV-1 infection. According to recently published research from the United States, "To date, attempts to eliminate HIV-1 infection from its latent reservoirs, a prerequisite for the development of a curative treatment strategy for HIV-1 infection, have been unsuccessful. ...
http://www.aegis.org/pubs/aidswkly/2005/aw050401.html
File Name: aw050401.html, Size: 9KB, Last Modified: Thursday, May 21, 2009 at 9:26:46 PM
Abstract: A review of representative cases of invasive aspergillosis was conducted to describe current treatment practices and outcomes. Eighty-nine physicians experienced with aspergillosis completed case forms on 595 patients with proven or probable invasive aspergillosis diagnosed using modifications of the Mycoses Study Gro ...
http://www.aegis.org/aidsline/2000/nov/a00b1037.html
File Name: a00b1037.html, Size: 11KB, Last Modified: Tuesday, November 28, 2000 at 8:12:04 PM
Abstract: Amphotericin B is frequently used for the treatment of fungal infections of immunocompromised individuals. Whereas immunomodulatory side effects of this agent are known, the influence of amphotericin B was studied in the model of murine Listeria monocytogenes infection. Treatment of L. monocytogenes-immune mice with a ...
http://www.aegis.org/aidsline/2000/jan/a0010629.html
File Name: a0010629.html, Size: 9KB, Last Modified: Friday, January 28, 2000 at 8:12:04 PM
Abstract: Cryptococcus neoformans is responsible for pulmonary and meningal infections in HIV patients. The lack of effective cellular cooperation caused by the low level of CD4+ cells, and the resistance of C. neoformans to phagocytosis allows growth and persistence of the yeast in the host. We describe here an in-vitro model ...
http://www.aegis.org/aidsline/1995/aug/m9580893.html
File Name: m9580893.html, Size: 10KB, Last Modified: Monday, August 28, 1995 at 8:12:04 PM
Abstract: OBJECTIVE: To report otic administration of parenteral amphotericin B 0.25% in sterile water. CASE SUMMARY: A 44-year-old HIV+ man was diagnosed with otitis externa. The patient s past medical history was remarkable for positive Coccidioides immitis serology for more than five months, essential hypertension, and Barre ...
http://www.aegis.org/aidsline/1994/sep/m9491023.html
File Name: m9491023.html, Size: 9KB, Last Modified: Wednesday, September 28, 1994 at 8:12:04 PM
Abstract: Flucanazole taken orally is more effective than weekly intravenous therapy with amphotericin B to prevent relapse of cryptococcal meningitis in AIDS patients after primary treatment with amphotericin B, write William G. Powderly et al. of the Washington University School of Medicine in St. Louis, Mo. A multicenter, r ...
http://www.aegis.org/news/ads/1992/ad920607.html
File Name: ad920607.html, Size: 10KB, Last Modified: Thursday, March 19, 1992 at 3:00:00 PM
Abstract: OBJECTIVE: To compare the efficacy of fluconazole with amphotericin B plus flucytosine in the treatment of cryptococcal meningitis. DESIGN: Patients were randomly assigned to oral fluconazole, 400 mg/d, for 10 weeks or to amphotericin B, 0.7 mg/kg body weight daily for 1 week, then three times weekly for 9 weeks combi ...
http://www.aegis.org/aidsline/1990/nov/m90b0415.html
File Name: m90b0415.html, Size: 11KB, Last Modified: Wednesday, November 28, 1990 at 8:12:04 PM
Abstract: SAN DIEGO--(BW HealthWire)--Dec. 10, 1997--NeXstar Pharmaceuticals Inc. (NASDAQ: NXTR) announced today that independent investigators presented new data supporting AmBisome (liposomal amphotericin B), the company s proprietary anti-fungal product. AmBisome is cleared for use in the United States as empirical therap ...
http://www.aegis.org/news/bw/1997/bw971204.html
File Name: bw971204.html, Size: 10KB, Last Modified: Wednesday, December 10, 1997 at 3:00:00 PM
Abstract: DEERFIELD, Ill. and BOULDER, Colo.--(BW HealthWire)-- Aug. 12, 1997-- First Liposomal Amphotericin B Indicated for Empirical Therapy for Presumed Fungal Infections in Immunocompromised Patients Fujisawa USA , Inc. and NeXstar Pharmaceuticals, Inc. (NASDAQ:NXTR) announced today that the U.S. Food and Drug Administration ...
http://www.aegis.org/news/bw/1997/bw970807.html
File Name: bw970807.html, Size: 11KB, Last Modified: Friday, August 01, 1997 at 3:00:00 PM
Abstract: We reviewed the records of 106 patients with cryptococcal infections and the acquired immunodeficiency syndrome (AIDS) treated at San Francisco General Hospital. We examined four issues: the efficacy of treatment with amphotericin plus flucytosine as compared with amphotericin alone, the efficacy of suppressive therap ...
http://www.aegis.org/aidsline/1989/dec/m89c0339.html
File Name: m89c0339.html, Size: 10KB, Last Modified: Wednesday, January 07, 2009 at 5:23:44 AM
Abstract: Paclitaxel is a novel anti-cancer drug with a unique mode of action. During the past five years, it has emerged as a drug of choice for the treatment of ovarian and breast cancers, and is recently approved for Kaposi sarcoma. It is likely to become a useful anti-neoplastic agent for a wide range of other cancerous con ...
http://www.aegis.org/aidsline/2000/may/a0050082.html
File Name: a0050082.html, Size: 9KB, Last Modified: Sunday, May 28, 2000 at 8:12:04 PM
Abstract: Over the past 15 years, factors suh as corticosteroid treatment, cytotoxic chemotherapy, excessive use of broad spectrum antibiotics and HIV have led to an increased risk of serious fungal infections in both adults and pediatric patients. This increase in invasive fungal infections poses increasing difficulty in their ...
http://www.aegis.org/aidsline/2000/jan/a0010698.html
File Name: a0010698.html, Size: 9KB, Last Modified: Friday, January 28, 2000 at 8:12:04 PM
Abstract: Treatment with a low daily dose of amphotericin B (0.4 mg/kg) in AIDS patients with cryptococcal meningitis has been associated with low efficacy and high mortality. We report our successful clinical experiences on a higher daily dose of amphotericin B (0.8-1.0 mg/kg) monotherapy in treating cryptococcal meningitis fr ...
http://www.aegis.org/aidsline/1999/dec/a99c0815.html
File Name: a99c0815.html, Size: 9KB, Last Modified: Tuesday, December 28, 1999 at 8:12:04 PM
Abstract: PRINCETON, N.J., Aug. 24 /PRNewswire/ -- The Liposome Company, Inc. (Nasdaq: LIPO) today announced that it has received regulatory approval for ABELCET(R) (Amphotericin B Lipid Complex Injection) from the Ministry of Health in Belgium . The indication for ABELCET(R) is for the treatment of invasive fungal infections in ...
http://www.aegis.org/news/pr/1999/pr990828.html
File Name: pr990828.html, Size: 9KB, Last Modified: Tuesday, August 24, 1999 at 3:00:00 PM